| 2.15 -0.02 (-0.92%) | 10-13 11:31 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.86  |
1-year : | 3.07 |
| Resists | First : | 2.45 |
Second : | 2.63 |
| Pivot price | 2.34 |
|||
| Supports | First : | 2.16 | Second : | 1.79 |
| MAs | MA(5) : | 2.2 |
MA(20) : | 2.37 |
| MA(100) : | 2.84 |
MA(250) : | 2.91 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 8.7 | D(3) : | 9.7 |
| RSI | RSI(14): 35 |
|||
| 52-week | High : | 4.09 | Low : | 2.15 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BLRX ] has closed above bottom band by 24.3%. Bollinger Bands are 4.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.35 - 2.36 | 2.36 - 2.37 |
| Low: | 2.13 - 2.14 | 2.14 - 2.16 |
| Close: | 2.15 - 2.17 | 2.17 - 2.19 |
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer. This compound is currently progressing through Phase 2 studies for metastatic pancreatic adenocarcinoma and Phase 1b trials for acute respiratory distress syndrome linked to COVID-19 and other viral infections. Additionally, Motixafortide is being investigated for its therapeutic potential in solid tumors and acute myeloid leukemia. The company's pipeline also includes AGI-134, an immuno-oncology agent presently undergoing Phase 1/2a clinical evaluations for various solid tumors. Furthermore, BioLineRx is advancing BL-5010, a custom-designed, proprietary pen-like device intended for the non-surgical removal of skin lesions. BioLineRx maintains strategic alliances, notably a collaboration with MSD in the domain of cancer immunotherapy, and an agreement with MD Anderson Cancer Center to explore Motixafortide combined with KEYTRUDA (pembrolizumab) for pancreatic cancer. They also have a licensing deal with Perrigo Company plc for the over-the-counter sale of BL-5010.
Fri, 09 Oct 2026
BioLineRx Ltd (NASDAQ: BLRX) Share Price, BLRX Stock News, BLRX Share Price & Updates - Kalkine
Thu, 08 Oct 2026
One covers lab models; another outlines a trial testing an experimental brain tumor treatment. - Stock Titan
Mon, 05 Oct 2026
BioLineRx Ltd. SEC Filing (Oct 5, 2026) - Stock Titan
Thu, 24 Sep 2026
Every proposal passed at BioLineRx (BLRX)’s September 23 annual meeting. - Stock Titan
Mon, 31 Aug 2026
BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update - PR Newswire
Mon, 31 Aug 2026
BioLine Rx Ltd (BLRX) (Q2 2026) Earnings Call Highlights: Advancing GLIX1 Pipeline and ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 4.14e+006 (%) |
| Held by Institutions | 3.4 (%) |
| Shares Short | 136 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.212e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 215.3 % |
| Return on Equity (ttm) | -19.9 % |
| Qtrly Rev. Growth | 1.39e+006 % |
| Gross Profit (p.s.) | -4.72 |
| Sales Per Share | -78.96 |
| EBITDA (p.s.) | 1.58571e+006 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 0.51 |
| Dividend | 0 |
| Forward Dividend | 145570 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|